Crispino S, Brenna A, Colombo D, Flores B, D'Amico S, Lissoni P, Barni S, Paolorossi F, Bratina G, Tancini G
Divisione di Radioterapia Oncologica, Nuovo Ospedale San Gerardo Monza, Milano-Italy.
Tumori. 1989 Dec 31;75(6):557-62. doi: 10.1177/030089168907500608.
Measurements of cell cycle kinetics have been found to correlate with the clinical course of patients with breast cancer. However, the thymidine labeling index and more rapid methods like flow cytometry remain complicated and costly. We assessed cell proliferation of 67 breast carcinomas by an immunoperoxidase procedure using a monoclonal antibody, Ki-67, which reacts with a nuclear antigen in proliferating cells. The percentage of Ki-67 positive cells ranged from 2% to 70%. Tumors with high mitotic rate, high nuclear grade, high histologic grade, and negative estrogen receptors had statistically higher Ki-67 labeling rates. We found no significant differences between the Ki-67 labeling rate and other clinical (age at diagnosis, menopausal status) or pathologic (necrosis, fibrosis, vascular invasion, lymphatic invasion, cellular reaction, tumor size, lymph node metastases) features assessed. These results parallel previously reported data, and confirm that this immunohistochemical staining of breast carcinoma by Ki-67 monoclonal antibody can be considered a rapid and convenient method for assessing cell cycle kinetics. However, further studies, evaluating the correlation between Ki-67 labeling rate and prognosis are needed to better define the real usefulness of this analysis in clinical practice.
已发现细胞周期动力学测量结果与乳腺癌患者的临床病程相关。然而，胸腺嘧啶核苷标记指数以及诸如流式细胞术等更快速的方法仍然复杂且昂贵。我们使用一种单克隆抗体Ki-67，通过免疫过氧化物酶法评估了67例乳腺癌的细胞增殖情况，该抗体与增殖细胞中的一种核抗原发生反应。Ki-67阳性细胞的百分比范围为2%至70%。有丝分裂率高、核分级高、组织学分级高以及雌激素受体阴性的肿瘤，其Ki-67标记率在统计学上更高。我们发现，在评估的Ki-67标记率与其他临床特征（诊断时年龄、绝经状态）或病理特征（坏死、纤维化、血管侵犯、淋巴侵犯、细胞反应、肿瘤大小、淋巴结转移）之间没有显著差异。这些结果与先前报道的数据一致，并证实通过Ki-67单克隆抗体对乳腺癌进行的这种免疫组织化学染色可被视为评估细胞周期动力学的一种快速便捷的方法。然而，需要进一步研究评估Ki-67标记率与预后之间的相关性，以便更好地确定该分析在临床实践中的实际用途。
